Evaluation of the Success of Pulsed Dye Laser 595nm in the Treatment of Rosacea | ||
Journal of Bioscience and Applied Research | ||
Article 5, Volume 11, Issue 3, September 2025, Pages 776-790 PDF (1.43 M) | ||
Document Type: Original Article | ||
DOI: 10.21608/jbaar.2025.453704 | ||
Authors | ||
Ali Fadhil Al-Saadi1; Noor Saud Al-Janabi2; Mohammed Al-Daraji* 3 | ||
1.Center of Dermatology\ Baghdad Medical City, Iraq | ||
2Center of Dermatology\ Baghdad Medical City, Iraq | ||
3College of Medicine, Ibn Sina University for Medical and Pharmaceutical Sciences, Iraq | ||
Abstract | ||
Rosacea is a common, chronic inflammatory skin condition characterized by erythema, flushing episodes, and inflammatory lesions. Light-based treatments available with great fame in the management of rosacea, notably pulsed dye lasers (PDL), have revolutionised the management of rosacea. This is a prospective therapeutic intervention study done at the Centre of Dermatology and Venereology, Medical City, Baghdad, Iraq. The patients included fifty patients with Erythematotelangiectatic Rosacea (29) and Papulopustular Rosacea (21). Sessions of pulsed dye laser were administered in between 2 and 6 sessions monthly, and the time of follow-up was three months after the last session. Fifty participants completed the research. The majority of subjects were females (84%). In the group, 58% had erythematotelangiectatic rosacea and 42% papulopustular rosacea. Paired samples t-test over 20 months of research showed a significantly better response of each subtype of the disease (P=0.000). Also, the difference in response based on the subtype of rosacea was meaningful in favor of the papulopustular group (P=0.000). Pulsed dye laser therapy is effective and safe in the management of both erythematotelangiectatic and papulopustular subtypes of rosacea, with significant results, particularly noted in papulopustular rosacea, but without significant side effects. | ||
Keywords | ||
Pulsed; Dye Laser; Rosacea | ||
Statistics Article View: 25 PDF Download: 18 |